INTRODUCTION
Ventricular septal defects (VSD) are the most common congenital cardiac defects and account for up to 30% of all congenital cardiac lesions.
(1) Postinfarction VSDs and trauma are responsible for the acquired forms of the defect.
Haemodynamic effects are related to the size of the left to right shunt and vary according to the size of the defect, from negligible to cardiac failure and pulmonary hypertension. Some smaller defects have a high likelihood of spontaneous closure, whilst larger defects persist through adulthood.
Long-term complications of VSDs include infective endocarditis, prolapse of aortic cusps with regurgitation, arrhythmias and pulmonary hypertension, which may lead to Eisenmenger syndrome.
Percutaneous closure of ventricular septal defects in childhood
Surgery is regarded as the golden standard in the management of large VSDs. However, percutaneous intervention has progressed markedly over the past decade and opened up new avenues of closure for certain VSDs.
Since Lock used the Rashkind double-umbrella device in 1988 to close muscular VSDs, numerous other devices such as coils, Button device, Cardioseal and other have been used. (2) Currently, the Amplatzer muscular and perimembranous VSD devices are the only occluders specifi cally designed for VSD closure and are probably the most universal devices implanted for this purpose.
ANATOMY OF A VSD
Different types of "simple" VSDs have been described according to their anatomical location. By far the most common are perimembranous VSD (70 -80%), muscular VSD (5-10%) and inlet VSD (5-10%). VSD is also an element of atrioventricular septal or atrioventricular canal defects (AVSD)
as well as more complex lesions, but these fall outside the scope of this discussion.
Anderson uses the anatomical relationships as viewed from the right ventricle as the primary criterion to describe the defect (3) (see Figure 1 ).
The VSDs can thus be placed in three groups:
1. Perimembranous defects -lie adjacent to the area of continuity between atrioventricular and arterial valves.
2. Muscular defects -usually enclosed within the muscular interventricular septum and can be between inlet, outlet or apical areas.
3. Doubly committed defects -these are directly related to the aortic and pulmonary valves.
It is important to recognise the fact that the membranous septum is directly confl uent with the area of fi brous continuity between the aortic and mitral valve (as viewed from the left ventricle). It is also related to the fi brous tissue that occupies the space between the non-coronary and right coronary cusps of the aortic valve. On the right ventricular aspect, the membranous septum is crossed by the hinge point of the septal leafl et of the tricuspid valve that divides it into atrioventricular and interventricular components.
This is an important anatomical landmark, since the conduction tissue penetrates this septum from the triangle of Koch and then runs in the crest of the membranous septum, sandwiched between fi brous and muscular septal components.
A defect in the membranous septum should always have the fi brous continuity between aortic and tricuspid valves at its posteroinferior margin.
This continuity is an important feature of perimembranous defects. Defects 
VSD CLOSURE Indications for closure
General indications for closure in unrestrictive VSD include symptomatic VSD and reversible pulmonary hypertension (pulmonary resistance < 7
Woods Units). 
Amplatzer VSD devices
The Amplatzer group of VSD devices (AGA Medical Corporation) are made of a nickel and Titanium alloy, Nitinol, which consists of 55% nickel Three devices for the different defects are available: muscular, membranous and post-infarct VSD devices. The membranous VSD occluder has an asymmetrical left ventricular disc with a shorter aortic component to avoid impingement of the aortic valve, whilst the post-infarct device has a longer waist and discs to accommodate the thicker adult interventricular septum. The muscular and membranous VSD devices are available in sizes ranging from 4-18mm and the post infarct device from 16-24mm. Delivery sheath size for muscular and membranous devices range from 6 -9 French.
Technique
Compared to patent ductus and atrial septal defect closure, VSD closure is considerably more complicated. It is thus important to recognise that this procedure should only be undertaken in units with suffi cient skill, knowledge, adequate equipment and surgical backup.
Complete details of the procedure have been described, (2, 6) Access is usually gained via the femoral artery and vein, although the right internal jugular vein may be used for certain muscular VSDs. Activated clotting time is maintained above 200 seconds throughout the procedure.
The device selected is usually 1 -2mm larger than the maximal diameter of the defect as assessed by TEE and angiography, although there is a move not to exceed the maximum diameter of the defect by much. Balloon sizing is hardly ever used, since the interventricular septum is regarded to be a non-stretchable structure.
Normally, the VSD is crossed from the left ventricle using a right coronary 
Other techniques of implantation
The device may also be implanted during surgery as an element of the so-called hybrid procedures. This may be accomplished with or without cardiopulmonary bypass. Usually the device is implanted by direct perforation of the right ventricle under TEE or epicardial echocardiographic guidance.
RESULTS OF PERCUTANEOUS CLOSURE

Muscular VSDs
Results largely depend on the type of device used and thus vary widely. Successful implantation is usually possible in most patients -95% according to the preliminary European report. (7) Some devices had residual shunts ranging from 25 -60%. As with the ASD devices, early residual leaks are common and success is best assessed looking at closure after 12 months. Amplatzer muscular occluders were reported to have occlusion rates of up to 93% after 12 months. (8) (9) (10) (11) (12) Residual shunting that remained was mostly classifi ed as trivial. Residual shunting of varying degrees is also common after surgery, occurring in up to 53% of cases. (4) 
Perimembranous VSDs
The Amplatzer membranous device is the only device specifi cally designed for this lesion. These lesions are technically particularly challenging. Satisfactory device impantation is possible in up to 97% of patients with a one-year complete closure of between 90 -100% in reported series (5) , (12) (13) (14) (15) (16) (17) depending on the complexity of the lesion. Recently, muscular VSD occluders were used with success to occlude perimembranous VSDs in patients with signifi cant aneurysm formation present. (18) Concerns have been raised whether this is an acceptable alternative to surgery, as the complication rate in some studies has been unacceptably high, particularly with regard to the development of heart block. (12 14 16) 
COMPLICATIONS
Haemolysis
This complication is usually associated with residual shunt after attempted device closure and may occur in 0.8% of cases. (15) In some instances it may be severe and transient renal failure (19) and needs for blood transfusion have been described. It has been suggested that it may be minimized by soaking the device in the patient's own blood pre-implantation.
Air embolism
This is an avoidable complication and can easily be avoided by paying meticulous attention to technique during catheter and wire exchanges.
Device embolisation
Both systemic and right heart embolisation of the device may occur and has been reported in up to 2% of cases. It seems to be related to operator experience, and highlights the importance of continuous TEE monitoring during the procedure. Operators should be familiar with retrieval techniques and all necessary equipment for retrieval should be available. Surgical backup is also considered essential.
Valvular regurgitation
The device may infl uence function of any of the valves, but especially with the membranous device, aortic and tricuspid regurgitation should actively be looked for with TEE prior to release of the device. It seems that if a minimum distance of 4mm from the aortic valve is observed, aortic regurgitation usually does not occur. Signifi cant aortic regurgitation developed in up to 15% in one series. (5) Mild aortic regurgitation was more common, but some of the regurgitation was transient and improved after six months.
Cardiac perforation
Complications of this nature are usually related to catheter and/or guide wire perforation of the cardiac chambers. This may lead to pericardial effusion, but neither tamponade nor delayed effusion related to the device has been described to date.
Dysrhythmias
During catheter and device manipulation temporary dysrhythmias, usually ventricular, are common. Right bundle branch block occurred in only 6% of patients (5) compared to up to 64% of reported surgical series (4, 20) . Complete heart block may also come about during the procedure, but cases of delayed development of complete block have been described. Most respond to treatment with steroids and anti-infl ammatory agents (21) , but permanent pacemaker implantation has also been necessary -the latter especially in cases of delayed atrioventricular block. (12) It is therefore imperative to have an experienced anaesthetist in theatre during the procedure. Knowledgeable personnel should also regularly follow up these children. Complete heart block most often follows implantation of the membranous VSD device. The exact cause is not known, but local trauma with haematoma due to manipulation of catheters and guide wires during catheterisation and infl ammatory response to the device or mechanical compression due to continued expansion of the device may be responsible for complete block, which occurs in up to 3.5% of procedures. This compares favourably to surgery, where complete heart block may occur in up to 3.1% of children. (4) 
Other
Although rare, serious complications, such as death, have occurred in 2-3% of patients. In surgical procedures, death was reported in 0 -4,3% of cases after 1980. (4) Recently, the fi rst case of endocarditis developing postimplantation, which was successfully treated with conservative measures, was reported. (22) 
POST-INFARCTION VSD
Post-infarction VSD is a serious complication and without treatment mortality may be more than 90%. Even with surgical closure, mortality varies from 19 -46%. Closure using percutaneous devices has had promising results, although frequently associated with residual shunts. Mortality was comparable to surgery (< 28%). Transcatheter closure of recurrent post-infarction VSD following patch repair is currently probably the treatment of choice. (23) (24) (25) 
CONCLUSION
Transcatheter management of ventricular septal defect is now feasible for a wide variety of muscular and perimembranous VSDs. The Amplatzer VSD devices are specifi cally designed for VSD occlusion and seem effective and safe. Other devices, designed for other lesions, should only be considered in individual cases. Percutaneous closure should only be attempted on properly selected patients in units with suffi cient experience and suitable echocardiographic equipment, together with surgical backup. The closure of perimembranous defects is not as yet routinely done.
PERCUTANEOUS CLOSURE OF VENTRICULAR SEPTAL DEFECTS IN CHILDHOOD
Surgical VSD closure remains the golden standard for routine VSD closure with a mortality rate of 0 -2.3%. (26) However, the signifi cant progress in the development of percutaneous devices cannot be ignored and in certain specifi c settings, like muscular VSDs and post-infarction VSDs, provide for an acceptable and attractive alternative treatment. This might be approached as an independent percutaneous intervention or in a hybrid fashion (with or without cardiopulmonary bypass).
Peri-operative mortality in the post-infarction VSD group still ranges from 16 -49 % and percutaneous closure in these extremely ill patients might become the treatment of choice for isolated post-infarction VSD in future.
The perimembranous group, which constitutes 70% of VSDs, still raises concerns. As mentioned above, a 4 mm muscular rim is required, the device can impact on (especially) aorta valve function, it cannot be used in children of less than 8 kg in weight and it causes heart block in up to 3.2%.
Heart block incidence after VSD closure is <1%. (27) The incidence of haemolysis and residual VSD (93% closure at one year), remains of concern, as well as device embolisation.
The published series of device closures mostly refers to older children with weights in excess of 8 kilograms (restrictive VSDs), but exclude small, growth compromised children with large VSDs, the "bread and butter" referral for surgery. It will be an erroneous belief to postpone surgical closure in this group in favour of later device closure. This is an exciting and potentially very useful development, which we as surgeons should approach with an open, though evidence based, mind.
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